Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trial of M4344 and Niraparib in PARP Resistant Recurrent Ovarian Cancer
NCT04149145Phase 1Withdrawn
- Sponsor
- University of Alabama at Birmingham
- Start
- May 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of gartisertib in ovarian cancer, sponsored by University of Alabama at Birmingham. Primary endpoints: Percentage of patients with treatment emergent adverse events at 1 year and Maximum tolerated dose of M4344 and Niraparib at 1 year. Planned start May 2023; status: withdrawn.
02
Drugs
gartisertib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04149145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04149145.